Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.

about

Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.

Item

http://www.wikidata.org/entity/Q47559036

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Brief Communication; A Heterol ...... nticancer Vaccination in Mice.

@en

Brief Communication; A Heterol ...... nticancer Vaccination in Mice.

@nl

type

Item

label

Brief Communication; A Heterol ...... nticancer Vaccination in Mice.

@en

Brief Communication; A Heterol ...... nticancer Vaccination in Mice.

@nl

prefLabel

Brief Communication; A Heterol ...... nticancer Vaccination in Mice.

@en

Brief Communication; A Heterol ...... nticancer Vaccination in Mice.

@nl

P1476

Brief Communication; A Heterol ...... Anticancer Vaccination in Mice

@en

P2093

Amelia S Aitken

http://www.w3.org/2001/XMLSchema#string

John C Bell

http://www.w3.org/2001/XMLSchema#string

Marie-Claude Bourgeois-Daigneault

http://www.w3.org/2001/XMLSchema#string

Nikolas T Martin

http://www.w3.org/2001/XMLSchema#string

P2860

Oncolytic Viruses: Therapeutics With an Identity Crisis

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.

Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.

Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

Going viral with cancer immunotherapy.

Targeting tumors with salmonella Typhimurium- potential for therapy.

Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer.

Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines

P304

125-129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CJI.0000000000000208

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dominic G Roy

Subash Sad

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29293165

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

5895163

http://www.w3.org/2001/XMLSchema#string